Results 71 to 80 of about 1,612 (203)
Amyloid neuropathy is caused by deposition of insoluble β‐pleated amyloid sheets in the peripheral nervous system. It is most common in: (1) light‐chain amyloidosis, a clonal non‐proliferative plasma cell disorder in which fragments of immunoglobulin, light or heavy chain, deposit in tissues, and (2) hereditary transthyretin (ATTRv) amyloidosis, a ...
Pitcha Chompoopong +3 more
wiley +1 more source
Istradefylline/L‐DOPA Parkinson's disease therapy and energy coupling
Abstract Background Both dopamine and adenosine are physiologically involved in cellular energy metabolism. Aim Novel approaches targeting delaying progression strategies for Parkinson's disease (PD) examined the effects of long‐term use of A2AR antagonist/istradefylline (IST) adjunct to L‐DOPA (LD), nutshell IST‐LD, with an expected energy coupling ...
Naomi Kanzato +2 more
wiley +1 more source
Clinical presentation and long-term follow-up of dopamine beta hydroxylase deficiency [PDF]
Dopamine beta hydroxylase (DBH) deficiency is an extremely rare autosomal recessive disorder with severe orthostatic hypotension, that can be treated with L-threo-3,4-dihydroxyphenylserine (L-DOPS).
Deinum, Jaap +13 more
core +2 more sources
Analysis of L-DOPA and Droxidopa Binding to Human Beta 2-Adrenergic Receptor [PDF]
Andrea Catte +4 more
openalex +1 more source
Abstract Introduction This study aimed to examine the associations of vitamin D receptor activators (VDRA) and calcimimetics use with falls. Methods This is a prospective cohort study on hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns Study. We excluded those who were unable to walk.
Miho Murashima +6 more
wiley +1 more source
Efficacy and Safety of Elobixibat in Parkinson's Disease with Chronic Constipation: CONST‐PD Study
Abstract Background Chronic constipation is a common digestive complication of Parkinson's disease (PD). Objectives To verify the usefulness of elobixibat, an ileal bile acid transporter inhibitor, for chronic constipation in PD. Methods This double‐blind, placebo‐controlled study consisted of a 2‐week observation/washout period and a 4‐week treatment ...
Taku Hatano +30 more
wiley +1 more source
Abstract Hereditary transthyretin (ATTRv; v for variant) amyloidosis is a rare, multisystem, progressive, and fatal disease in which polyneuropathy is a cardinal manifestation. Due to a lack of United States (US)‐specific guidance on ATTRv amyloidosis with polyneuropathy, a panel of US‐based expert clinicians convened to address identification ...
Chafic Karam +6 more
wiley +1 more source
Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology [PDF]
Background and objective Non-motor symptoms frequently develop throughout the disease course of Parkinson’s disease (PD), and pose affected individuals at risk of complications, more rapid disease progression and poorer quality of life.
Becktepe, Jos +11 more
core +1 more source
Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment [PDF]
Robert A. Hauser +6 more
openalex +1 more source
A Path Difficult to Tread: Pure Autonomic Failure, A Case Report [PDF]
Introduction - Pure autonomic failure is a rare disorder characterized by orthostatic hypotension, absence of a compensatory rise in heart rate, and abnormal autonomic functions.
Dalbah, Rami +5 more
core +1 more source

